IRVINE, Calif., July 6 /PRNewswire-FirstCall/ -- Endologix, Inc.
(Nasdaq: ELGX), developer of minimally invasive treatments for
aortic disorders, announced today that it has appointed
Todd Abraham to the newly created
position of Vice President of Operations. Mr. Abraham will be
responsible for managing all of Endologix's day-to-day operations
and will report to John McDermott,
President and Chief Executive Officer.
Mr. McDermott, said, "Todd
Abraham is a 25 year veteran of the medical device industry,
with an impressive track record in manufacturing, operational
management and commercialization. His experience is complemented by
his endovascular product experience at Edwards Lifesciences and
Cordis Corporation. He is an important addition to our management
team as we execute on our strategy to expand our product portfolio
to address the entire aortic stent graft market opportunity."
Prior to joining Endologix, Mr. Abraham held several management
positions at Edwards Lifesciences, including Vice President,
Glucose Monitoring; Vice President, Global Supply Chain &
Logistics; and Vice President, Manufacturing. Prior to
joining Edwards, Mr. Abraham was Vice President & General
Manager of Sterilis, Inc., a development stage start-up focused on
minimally invasive products for gynecology, urology and general
surgery. Mr. Abraham began his career at Cordis Corporation
(acquired by Johnson & Johnson in 1996), where he spent 14
years in positions of increasing responsibility, gaining
operational and product development experience across several
cardiovascular product categories and manufacturing lines.
Mr. Abraham received a B.A. in Economics from Duke University and completed graduate work in
Engineering Management at the University of
South Florida.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship product is
the Powerlink® System, which is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening
of the wall of the aorta, the largest artery in the body, resulting
in a balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
Forward-Looking Statements
Except for historical information contained herein, this news
release contains forward-looking statements, including the planned
expansion of Endologix's product portfolio, the accuracy of which
are necessarily subject to risks and uncertainties, all of which
are difficult or impossible to predict accurately and many of which
are beyond the control of Endologix. Many factors may cause actual
results to differ materially from anticipated results, including
the success of sales efforts for the Powerlink System, product
research and development efforts, and other economic, business,
competitive and regulatory factors. The Company undertakes no
obligation to update its forward looking statements. Please refer
to the Company's Annual Report on Form 10-K for the year ended
December 31, 2009, and the Company's
other filings with the Securities and Exchange Commission, for more
detailed information regarding these risks and other factors that
may cause actual results to differ materially from those expressed
or implied.
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix,
Inc.
|
The Ruth Group
|
|
John McDermott,
CEO
|
Nick Laudico (646) 536-7030
|
|
(949)
595-7200
|
Zack Kubow (646) 536-7020
|
|
www.endologix.com
|
|
|
|
|
SOURCE Endologix, Inc.